Marinomed Biotech AG (VIE:MARI)

Austria · Delayed Price · Currency is EUR

11.00

+0.20 (1.85%)

Jun 5, 2026, 5:37 PM CET

-38.20% (1Y)

Market Cap	21.99M +1.4%
Revenue (ttm)	7.96M +66.1%
Net Income	18.02M
EPS	9.79
Shares Out	2.00M
PE Ratio	1.12
Forward PE	8.87
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,675
Open	11.20
Previous Close	10.80
Day's Range	10.20 - 11.20
52-Week Range	8.60 - 21.00
Beta	-0.19
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Marinomed Biotech AG

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly know... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2006

Employees 32

Stock Exchange Vienna Stock Exchange

Ticker Symbol MARI

Full Company Profile

Financial Performance

Financial Statements

News

Marinomed Biotech AG Transcript: Austrian Select Conference

The company is advancing two late-stage assets, Budesolv and Tacrosolv, with successful clinical results and is in advanced partnering discussions targeting large global markets. Financial restructuring and a recent capital increase support a path to profitability and debt-free status by mid-next year.

6 weeks ago - Transcripts

Marinomed Biotech AG Slides: Austrian Select Conference

Marinomed Biotech AG has posted slides in relation to its latest quarterly earnings report, which was published on April 23, 2026.

6 weeks ago - Filings

Marinomed Biotech AG Annual report: H2 2025

Marinomed Biotech AG has published its H2 2025 annual report on April 22, 2026.

6 weeks ago - Filings

Marinomed Biotech AG Transcript: GBC International Investment Forum

The company is advancing two late-stage assets, Budesolv and Tacrosolv, targeting large, underserved markets with patented, fast-acting, and preservative-free formulations. Partnering discussions are ongoing globally, with revenue expected from upfront and milestone payments before full regulatory approval.

3 months ago - Transcripts

Marinomed Biotech AG Quarterly report: H1 2025

Marinomed Biotech AG has published its H1 2025 quarterly earnings report on September 17, 2025.

9 months ago - Filings

Marinomed Biotech AG Transcript: Health Care Conference

The presentation highlighted a proprietary solubilization technology enabling disruptive nasal spray products, a strong financial turnaround through asset sales and debt reduction, and a clear strategy for global market expansion via partnerships. Key product Budesolf is poised for commercialization, with additional pipeline and service revenues supporting growth.

1 year ago - Transcripts